TerminatedPHASE1, PHASE2NCT02984085

Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB.

Studying Dystrophic epidermolysis bullosa

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Holostem s.r.l.
Principal Investigator
Michele De Luca, MD/Professor
Holostem s.r.l.
Intervention
Genetically corrected cultured epidermal autograft (ATMP)(drug)
Enrollment
3 enrolled
Eligibility
6-54 years · All sexes
Timeline
2017 – 2018

Study locations (1)

Collaborators

Paracelsus Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02984085 on ClinicalTrials.gov

Other trials for Dystrophic epidermolysis bullosa

Additional recruiting or active studies for the same condition.

See all trials for Dystrophic epidermolysis bullosa →

← Back to all trials